Mankind Pharma shares rose over 2% in morning trade after the company reported impressive Q2 FY25 results.
Revenue surged 14% year-on-year to ₹3,077 crore, driven by robust domestic market growth and a strong 57% YoY increase in exports. Domestic revenue reached ₹2,796 crore, an 11% YoY rise, while exports contributed ₹281 crore.
EBITDA climbed 24% YoY to ₹853 crore, achieving a margin of 27.7%. Profit After Tax (PAT) saw a 29% YoY increase, hitting ₹659 crore with a PAT margin of 21.4%.
As of 9:31 am, Mankind Pharma shares were trading 1.57% higher at Rs 2,756.75 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
